\
&
Contact us
\
&
Contact us
This was 9 months ago
LocationEuropean Convention Center Luxembourg
Space4defence, the European Defence Fund Industry & Matchmaking Day 2025 will take place on the 26th of February 2025, in the European Convention Center Luxembourg, in Luxembourg.
This matchmaking day will bring together innovative startups, SMEs, research organisations and large companies interested in and eligible to apply to the calls for proposals of the European Defence Fund (EDF).
The aim is to help them connect with partners who have specific expertise or solutions, form consortia, and spark new ideas through collaborative meetings.
Participants will be able to present their solutions and explore collaboration opportunities within the space domain in view of the EDF 2025 calls for proposals. Startups and SMEs will have the opportunity to pitch their companies and solutions.
You can find more information and register yourself here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health AI Continent Deployment: Best use of technologies
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
